A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425. - Wikidata - awgldk - TriplyDB

A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425.

A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425.

http://www.wikidata.org/entity/Q37348243

about

Cardioprotective interventions for cancer patients receiving anthracyclines Pediatric Hodgkin lymphoma: biomarkers, drugs, and clinical trials for translational science and medicine.Staging Evaluation and Response Criteria Harmonization (SEARCH) for Childhood, Adolescent and Young Adult Hodgkin Lymphoma (CAYAHL): Methodology statement.ABVE-PC and modified BEACOPP regimen in Indian children with Hodgkin lymphoma: Feasibility and efficacy End-of-radiation PSA as a novel prognostic factor in patients undergoing definitive radiation and androgen deprivation therapy for prostate cancer Cardiovascular disease in adult survivors of childhood cancer.Use of appropriate initial treatment among adolescents and young adults with cancer.Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk hodgkin lymphoma: a report from the Children's Oncology Group Study AHOD0031 BEACOPP chemotherapy is a highly effective regimen in children and adolescents with high-risk Hodgkin lymphoma: a report from the Children's Oncology Group.Managing chemotherapy-related cardiotoxicity in survivors of childhood cancers.Dexrazoxane as a cardioprotectant in children receiving anthracyclines Lessons from the past: opportunities to improve childhood cancer survivor care through outcomes investigations of historical therapeutic approaches for pediatric hematological malignancies.A phase 2 study of bortezomib in combination with ifosfamide/vinorelbine in paediatric patients and young adults with refractory/recurrent Hodgkin lymphoma: a Children's Oncology Group study.Cardioprotection and Second Malignant Neoplasms Associated With Dexrazoxane in Children Receiving Anthracycline Chemotherapy: A Systematic Review and Meta-Analysis.Late Mortality After Dexrazoxane Treatment: A Report From the Children's Oncology Group.Surveillance computed tomography imaging and detection of relapse in intermediate- and advanced-stage pediatric Hodgkin's lymphoma: a report from the Children's Oncology Group Long-term results of CCG 5942: a randomized comparison of chemotherapy with and without radiotherapy for children with Hodgkin's lymphoma--a report from the Children's Oncology Group Response-dependent and reduced treatment in lower risk Hodgkin lymphoma in children and adolescents, results of P9426: a report from the Children's Oncology Group.Advances in paediatric cancer treatment Reduction in Late Mortality among 5-Year Survivors of Childhood Cancer.Future vision for the quality assurance of oncology clinical trials.Targeted therapy for Hodgkin lymphoma and systemic anaplastic large cell lymphoma: focus on brentuximab vedotin.The role of antioxidants in the era of cardio‑oncology.Incidence of myelodysplastic syndromes in patients receiving concurrent myelosuppressive chemotherapy and pegfilgrastim.Management of relapsed and refractory classical Hodgkin lymphoma in children and adolescents.Classical Hodgkin's lymphoma arising in different host's conditions: pathobiology parameters, therapeutic options, and outcome.Adolescents with Hodgkin lymphoma: old children or young adults?Management of children with high-risk Hodgkin lymphoma.Children's Oncology Group's 2013 blueprint for research: Hodgkin lymphoma.Controversies in the role of radiotherapy in the treatment of pediatric Hodgkin lymphoma.Stratification of treatment intensity in relapsed pediatric Hodgkin lymphoma.ACR Appropriateness Criteria Pediatric Hodgkin Lymphoma.Patterns of relapse from a phase 3 Study of response-based therapy for intermediate-risk Hodgkin lymphoma (AHOD0031): a report from the Children's Oncology Group Cardiac complications in childhood cancer survivors treated with anthracyclines.Pretransplant functional imaging and outcome in pediatric patients with relapsed/refractory Hodgkin lymphoma undergoing autologous transplantation.Hodgkin Lymphoma: Current Status and Clinical Trial Recommendations.The evolving role of radiation therapy in pediatric Hodgkin's disease.Outcome of pediatric advanced Hodgkin lymphoma treated with ABVD and predictors of inferior survival: a multicenter study of 186 patients.Management of Hodgkins Lymphoma: ICMR Consensus Document.Childhood Hodgkin International Prognostic Score (CHIPS) Predicts event-free survival in Hodgkin Lymphoma: A Report from the Children's Oncology Group.

P2860

Q24236338-D12212B3-1FC9-4151-BFA6-3F3D16B3EE95 Q30248284-BC2F7E76-FCB2-48AD-B301-4073D20B9E99 Q30313537-13EE7049-2561-4147-ABB8-F2128C4A8DA1 Q33432165-86A31B18-603B-4DCA-9256-0778B6049DAF Q33676155-0E0C320B-E369-46AF-96CF-EBA833D769BC Q34042984-8115E190-4E71-4035-ACA0-89AEBEE756AB Q34354175-02823A2E-5A0C-4002-AD21-BB58AEB29E85 Q34451778-474D4298-A1C7-44D1-91DA-D1C8BDC2FCEA Q34707420-E7B167FF-55C6-478A-9330-763803AF20E4 Q35562745-48814AA0-40CD-4847-B347-6F56AFE476AA Q35583768-50B9A008-5F3B-4F99-9BE9-C91193D86F68 Q35667279-F60AF233-5D30-49C7-BFA0-A23C623140F1 Q35772357-33A1F3D2-B650-45CD-9D7F-F7FE4DDC064B Q35849444-8FD06FE1-761C-4262-9614-BB69B6BC7B9C Q35947024-C2B79E3D-BE55-4FD3-B7B5-D1431C74774E Q36025958-610068B2-7F31-4411-959F-E3100F0DE4BA Q36212381-C9F707D5-EAB1-4C13-B3FC-12AFBD89BD28 Q36309826-00F06A6B-4690-4ABD-9377-976BDEC72EE1 Q36508630-37BD028D-7423-4C6A-8AF6-CE3A3E40D3C6 Q36673832-A1D7A520-BE1C-4189-BA4D-CE78D338FCAB Q36686408-50816868-3863-4B30-8A39-7FBBB67E41A2 Q37412853-B3A27180-89BC-4DBB-90D4-5CC2CE8ADB11 Q37626273-C1B8D631-E576-496B-802D-26119C9CBFD4 Q37793644-F7650D42-31D4-43D9-ACFB-CCEF94A2A20A Q37816470-9675E82B-CF3C-4027-BA56-6DB0D44EB445 Q37832198-468ECF0E-964D-4DDA-969A-60EA92A96F8E Q37968278-9782D62E-3ECB-44DB-B797-EC01CF4E1127 Q37970408-ED1D19B8-29A3-481A-B19B-F5DE96C8A972 Q38068839-40E85338-F22C-4F74-BEA9-74AE04DA9F35 Q38131410-5435031E-DF42-4125-BD6E-EBB91EAAD91C Q38185983-8687B19D-AE96-4964-AFD3-29D71F3597F4 Q38195016-249195F5-6E25-441F-819C-E9D18F5AC094 Q38301247-6C4DEBD0-1C1C-4263-8CFA-A2BFD5766E7A Q38588167-A3DE313E-E1B3-4A14-8C4E-30BDF8FF0454 Q38684561-F236D7A4-4F98-4CC5-BD09-B8B092A04233 Q38775871-028D1419-D81C-499C-9008-0ED05F479C7E Q38823537-4AE5F23C-792C-433E-BCC3-4690E0A7F62C Q39129713-4096D750-C40B-4991-A09F-80904F9875AA Q39208309-FC28CF11-C361-4E9C-A355-81143CB3B090 Q39244757-491C1975-666C-4CEC-B444-22909E16037F

P2860

A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425.

http://www.wikidata.org/entity/Q37348243

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 07 July 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

A risk-adapted, response-based ...... ymphoma: the results of P9425.

@en

A risk-adapted, response-based ...... ymphoma: the results of P9425.

@nl

type

label

A risk-adapted, response-based ...... ymphoma: the results of P9425.

@en

A risk-adapted, response-based ...... ymphoma: the results of P9425.

@nl

prefLabel

A risk-adapted, response-based ...... ymphoma: the results of P9425.

@en

A risk-adapted, response-based ...... ymphoma: the results of P9425.

@nl

P1433

Q37348243-0D84766E-0713-49E2-96BC-9E21016BEA6E

P1476

Q37348243-C155B114-25DF-4EBA-A07A-7B46706381F5

P2093

Q37348243-08BF36A1-283C-456B-9836-9CDF70426E1C

Q37348243-0ADBE0C7-3C19-49C3-80C5-C61D26DCF079

Q37348243-1067B35B-AAC2-4BAD-8A7A-A536EE9CBE2C

Q37348243-139CEBC7-86C0-4D01-940B-B55CD1EE5AA2

Q37348243-9A4E6B4A-6BB0-46BC-B4E0-C4B8C994159C

Q37348243-A13FACDD-C042-4FE7-AC9E-FA46B9A40F29

Q37348243-B74A0408-4E34-4439-B327-43789CFDCE5B

Q37348243-C61DF244-CB8A-4315-A903-43D08818C18E

Q37348243-E2E53D1E-522F-45A9-AEED-A940A8336799

P2860

Q37348243-0263C43E-CE96-43FD-983F-0191BD1CA1E6

Q37348243-05B5C0B3-4CB2-4697-AC07-EE2B0F0D9BE5

Q37348243-18D72A0A-94C0-46F6-9942-79B05B5D50ED

Q37348243-1A1286CD-2732-4B6E-8C2F-9714E5FC87EC

Q37348243-1D5C4DBC-86C8-4ED9-BFC0-A83A55DC6BE4

Q37348243-1DDA9D09-D49D-4393-9274-12BC88154A30

Q37348243-2BEE5607-DE9A-4A2E-A587-E2939F5CEA04

Q37348243-388ECC64-578D-4DA0-96E2-3110DDD09B6E

Q37348243-400F4B57-AD1B-471F-8C96-F235B1722F48

Q37348243-42D6C624-9407-4119-8DBE-7E615097EA5C

P304

Q37348243-E3532D8A-3DBD-441A-9FB9-55F588528F2A

P31

Q37348243-CB192F45-AD91-4B95-82E4-D1D0F0A5FB6D

P356

Q37348243-7375D7A3-193F-43A7-B931-A5E3548DA0A7

P407

Q37348243-0A758B86-0C17-4B5A-B1A9-54682F237D4A

P433

Q37348243-B2DD99BA-F281-4592-BC40-6DB59A792A91

P478

Q37348243-EE102E4A-C28D-4377-88C8-E53EEEF7B335

P50

Q37348243-410564A2-261D-4751-A95E-F835E55E90FE

P577

Q37348243-0C2412A3-CFD1-4CF9-8F16-A56F42E23A84

P5875

Q37348243-348DF198-5DEB-45DB-9685-EC41D0E8E511

P698

Q37348243-9ACD776B-5829-47B5-96FF-97EC9E93B6B6

P921

Q37348243-F33B87FD-3314-4C90-824E-394FA601A586

P932

Q37348243-2CD90310-BB86-4035-BF5B-96161D5E0BE4

P356

BLOOD-2008-10-184143

P1433

P1476

A risk-adapted, response-based ...... ymphoma: the results of P9425.

@en

P2093

Allen Chauvenet

http://www.w3.org/2001/XMLSchema#string

Charles S Turner

http://www.w3.org/2001/XMLSchema#string

Cindy L Schwartz

http://www.w3.org/2001/XMLSchema#string

Doojduen Villaluna

http://www.w3.org/2001/XMLSchema#string

Louis S Constine

http://www.w3.org/2001/XMLSchema#string

Pedro A deAlarcon

http://www.w3.org/2001/XMLSchema#string

Richard Sposto

http://www.w3.org/2001/XMLSchema#string

Robert E Hutchison

http://www.w3.org/2001/XMLSchema#string

Wendy B London

http://www.w3.org/2001/XMLSchema#string

P2860

Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood

Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD

ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi

Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute

Twenty years of MOPP therapy for Hodgkin's disease

Localized childhood Hodgkin's disease: response-adapted chemotherapy with etoposide, bleomycin, vinblastine, and prednisone before low-dose radiation therapy-results of the French Society of Pediatric Oncology Study MDH90

Abnormalities of the thyroid in survivors of Hodgkin's disease: data from the Childhood Cancer Survivor Study.

Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial.

Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy.

American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects.

P304

2051-2059

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2008-10-184143

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

114

http://www.w3.org/2001/XMLSchema#string

P50

Steven E Lipshultz

P577

2009-07-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26653887

http://www.w3.org/2001/XMLSchema#string

P698

19584400

http://www.w3.org/2001/XMLSchema#string

P921

P932

2744567

http://www.w3.org/2001/XMLSchema#string